Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012 - PubMed (original) (raw)
doi: 10.1002/ejhf.496. Epub 2016 Feb 11.
Affiliations
- PMID: 26869252
- DOI: 10.1002/ejhf.496
Free article
Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012
Tonje Thorvaldsen et al. Eur J Heart Fail. 2016 May.
Free article
Abstract
Aims: In heart failure with reduced ejection fraction, drug and device therapy improve survival. We studied contemporary trends in utilization of evidence-based therapy and associated survival.
Methods and results: We studied 5908 patients with NYHA class II-IV heart failure, EF <30%, and duration of heart failure ≥6 months registered in the Swedish Heart Failure Registry between 2003 and 2012. Regression using generalized estimation equations was used to examine temporal trends in crude and risk-adjusted rates of utilization of evidence-based heart failure therapy and 30-day, 1-year, and 3-year survival. In 2003 vs. 2012, the risk-adjusted use of therapy and P-values for trends were as follows: renin-angiotensin system antagonists, 88% vs. 86% (P = 0.091); beta-blockers, 85% vs. 93% (P = 0.008); mineralocorticoid receptor antagonists, 53% vs. 42% (P < 0.001); CRT, 2.4% vs. 8.2% (P = 0.074); and implantable cardioverter-defibrillators, 4.0% vs. 10.7% (P = 0.004). During the same period, the risk-adjusted 30-day, 1-year, and 3-year survival was 92% vs. 94% (P = 0.532), 81% vs. 77% (P = 0.260), and 58% vs. 54% (P = 0.425), respectively.
Conclusions: In this large nationwide registry, over the last decade the use of evidence-based drug therapy was high and remained stable over time, but, despite an increased use of device therapy, the absolute use was poor. This was associated with an absence of improvement in survival. The improvements in therapy and prognosis over the last generation may be levelling off, and efforts should be directed at improving implementation of evidence-based therapy.
Keywords: Evidence-based therapy; Guidelines; Heart failure; Implementation; Outcomes; Utilization.
© 2016 The Authors. European Journal of Heart Failure © 2016 European Society of Cardiology.
Comment in
- Outcome improvement of patients with heart failure and reduced ejection fraction: has it ended in the new millennium?
Maggioni AP. Maggioni AP. Eur J Heart Fail. 2016 May;18(5):512-3. doi: 10.1002/ejhf.527. Epub 2016 Apr 27. Eur J Heart Fail. 2016. PMID: 27121569 No abstract available.
Similar articles
- Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS, Kunze KL, Lee JZ, Amin M, Neville MR, Almader-Douglas D, Killu AM, Madhavan M, Cha YM, Asirvatham SJ, Friedman PA, Gersh BJ, Mulpuru SK. Tseng AS, et al. Circ Arrhythm Electrophysiol. 2019 Jun;12(6):e006951. doi: 10.1161/CIRCEP.118.006951. Epub 2019 Jun 4. Circ Arrhythm Electrophysiol. 2019. PMID: 31159582 - The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M. Ambrosy AP, et al. J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133. doi: 10.1016/j.jacc.2013.11.053. Epub 2014 Feb 5. J Am Coll Cardiol. 2014. PMID: 24491689 - Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis.
Miller RJ, Howlett JG, Exner DV, Campbell PM, Grant AD, Wilton SB. Miller RJ, et al. Can J Cardiol. 2015 Jun;31(6):792-9. doi: 10.1016/j.cjca.2014.12.031. Epub 2015 Jan 7. Can J Cardiol. 2015. PMID: 26022990 Review. - Effect of Optimization of Medical Treatment on Long-Term Survival of Patients With Heart Failure After Implantable Cardioverter Defibrillator and Cardiac Resynchronization Device Implantation (from the French National EGB Database).
Massoullié G, Chouki C, Mulliez A, Rossignol P, Ploux S, Pereira B, Reuillard A, Jean F, Andronache M, Eschalier A, Motreff P, Clerfond G, Bordachar P, Authier N, Eschalier R. Massoullié G, et al. Am J Cardiol. 2018 Mar 15;121(6):725-730. doi: 10.1016/j.amjcard.2017.12.013. Epub 2018 Jan 3. Am J Cardiol. 2018. PMID: 29402420 - Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial.
Bristow MR, Saxon LA, Feldman AM, Mei C, Anderson SA, DeMets DL. Bristow MR, et al. JACC Heart Fail. 2016 Jul;4(7):521-535. doi: 10.1016/j.jchf.2016.02.019. Epub 2016 Jun 8. JACC Heart Fail. 2016. PMID: 27289408 Review.
Cited by
- Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.
Clephas PRD, Radhoe SP, Linssen GCM, Langerveld J, Plomp J, Smits JPP, Nagelsmit MJ, Rocca HB, Brugts JJ. Clephas PRD, et al. ESC Heart Fail. 2023 Apr;10(2):1481-1487. doi: 10.1002/ehf2.14285. Epub 2023 Feb 3. ESC Heart Fail. 2023. PMID: 36738129 Free PMC article. - Differences in medical treatment and clinical characteristics between men and women with heart failure - a single-centre multivariable analysis.
Norberg H, Pranic V, Bergdahl E, Lindmark K. Norberg H, et al. Eur J Clin Pharmacol. 2020 Apr;76(4):539-546. doi: 10.1007/s00228-019-02782-2. Epub 2020 Jan 3. Eur J Clin Pharmacol. 2020. PMID: 31897534 - Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction.
Stolfo D, Lund LH, Sinagra G, Lindberg F, Dahlström U, Rosano G, Savarese G. Stolfo D, et al. Eur Heart J Cardiovasc Pharmacother. 2023 Sep 20;9(6):526-535. doi: 10.1093/ehjcvp/pvad036. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 37204037 Free PMC article. - Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE-HF.
Clephas PRD, Malgie J, Schaap J, Koudstaal S, Emans M, Linssen GCM, de Boer GA, van Heerebeek L, Borleffs CJW, Manintveld OC, van Empel V, van Wijk S, van den Heuvel M, da Fonseca C, Damman K, van Ramshorst J, van Kimmenade R, van de Ven ART, Tio RA, van Veghel D, Asselbergs FW, de Boer RA, van der Meer P, Greene SJ, Brunner-La Rocca HP, Brugts JJ. Clephas PRD, et al. ESC Heart Fail. 2024 Feb;11(1):550-559. doi: 10.1002/ehf2.14604. Epub 2023 Dec 8. ESC Heart Fail. 2024. PMID: 38064176 Free PMC article. - Efficacy of guideline-directed medical treatment in heart failure with mildly reduced ejection fraction.
Zhang X, Sun Y, Zhang Y, Wang N, Sha Q, Yu S, Lv X, Ding Z, Zhang Y, Tse G, Liu Y. Zhang X, et al. ESC Heart Fail. 2023 Apr;10(2):1035-1042. doi: 10.1002/ehf2.14199. Epub 2022 Dec 15. ESC Heart Fail. 2023. PMID: 36519802 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials